NCT06388772已完成1 期
Phase I Clinical Study of Tolerability, Safety and Pharmacokinetics of QHRD106 Injection in Chinese Healthy Subjects With Single Doses
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 74
- 试验地点
- 1
- 主要终点
- Safety as assessed by incidence, severity, and causality of adverse events
研究概览
简要总结
The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of QHRD106 early in Chinese healthy subjects with single doses.
详细描述
Eight dose groups were initially set up. The experimental groups were increased from low to high dose according to the principle of increasing dose, and Placebo was added as the control group. All the selected subjects in the experimental group were given the drug once.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects, male and female equally;
- •Aged between 18 and 50 at the time of screening (including boundary values); Male weight ≥50.0kg, female weight ≥45.0kg; All subjects had a body mass index (BMI) between 19 and 28kg/m2 (including boundary values);
- •Participate voluntarily and sign informed consent to complete the experiment according to the research protocol.
排除标准
- •Subjects who meet one of the following conditions will not be enrolled in the trial:
- •a person who is allergic to, or is allergic to, 2 or more drugs or foods, or is known to have a history of allergy to the test preparation and any of its components or related preparations;
- •Patients with a history of clinically serious diseases such as nervous system, blood circulatory system, digestive system, urinary system, respiratory system, immune system, endocrine system, malignant tumor, mental and metabolic abnormalities, or any clinically significant diseases judged by researchers to be in an active period or unstable state;
- •Based on vital signs (including sitting blood pressure, pulse, and body temperature), physical examination, 12-lead electrocardiogram examination, and laboratory examination (including routine blood routine, urine routine, blood biochemistry, and coagulation function), the investigator determined that the abnormality was clinically significant;
- •postural hypotension;
- •α1-antitrypsin deficiency;
- •Patients with difficulty in venous blood collection;
- •People with a history of fainting needles and fainting blood;
- •A history of drug abuse within the last two years (including repeated and heavy use of various narcotic drugs and psychotropic substances for non-medical purposes);
- •Excessive smoking within 3 months before screening (average > 5 cigarettes/day) or unable to stop using any tobacco products during the test period or smokers within 48 hours before screening;
- •Excessive daily consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 1 cup =250mL) in the 3 months before screening;
- •alcoholics (i.e. men drinking more than 28 standard units per week, women drinking more than 21 standard units per week, 1 standard unit containing 14g of alcohol, such as 360mL beer or 45mL spirits with 40% alcohol or 150mL wine) or regular drinkers (i.e. more than 14 standard units per week) in the six months prior to screening;
- •Positive alcohol breath test (test result greater than 0.0mg/100mL);
- •Hepatitis B surface antigen (HBsAg), hepatitis C virus(HCV) antibody, syphilis antibody and human immunodeficiency virus(HIV) antibody test one or more positive;
- •Positive urine screening for drug abuse (including morphine, methamphetamine, ketamine, dimethylene dexamphetamine, tetrahydrocannabinol, cocaine);
- •Abnormal chest X-ray or CT findings with clinical significance;
- •Abdominal B-ultrasonography (liver, bile, pancreas, spleen and kidney) with abnormal results and clinical significance;
- •Severe acute bacterial, viral or fungal infection within 4 weeks prior to screening;
- •Patients who had used any protease drugs (such as chylase, indinavir sulfate, ritonavir, bortezomib, ixazomib citrate, etc.) within 4 weeks before screening;
- •Use of any prescription or over-the-counter drugs, as well as any functional vitamins or Chinese herbal products within 2 weeks prior to screening;
- •Blood donation or blood loss greater than 400mL within 3 months before screening (except physiological blood loss);
- •Vaccinated within 1 month before screening, or planned to be vaccinated during the study period and within 1 month after the study ends;
- •Those who had undergone surgery within 3 months prior to screening or planned to undergo surgery during the trial;
- •Participants who participated in any drug clinical trial as a subject within 3 months before enrollment;
- •have consumed a special diet (including grapefruit, chocolate, tea, cola, or any food or beverage containing caffeine, alcoholic beverage, or other food or beverage that affects the absorption, distribution, metabolism, or excretion of drugs) in the 48 hours prior to screening;
- •The subjects or their partners do not wish to use one or more non-drug contraceptive methods (such as total abstinence, condoms,contraceptive rings, ligation, etc.) for contraception during the trial period or have pregnancy plans within 3 months after the end of the study; Or screening women with positive pregnancy tests or breastfeeding women;
- •With magnetic resonance examination contraindications: metal implant, claustrophobia, etc.;
- •Other situations in which the investigator considers that participation in the trial may not be appropriate. -
研究组 & 干预措施
Part-A SAD in healthy subjects(Cohort 1-8)
Experimental
A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive QHRD106 by intramuscular-injection (im).
干预措施: QHRD106 Injection (Drug)
Part-B Healthy subjects SAD placebo
Experimental
A randomized, double-blinded, placebo-controlled, single ascending dose (SAD) study in healthy male and female subjects. Subjects will receive placebo by intramuscular-injection (im).
干预措施: placebo (Drug)
结局指标
主要结局
Safety as assessed by incidence, severity, and causality of adverse events
时间窗: Up to 36 days after final dose
The frequency and number of adverse events, adverse reactions and serious adverse
Plasma measurements of QHRD106
时间窗: Up to 36 days after final dose
The concentration of a single dose was measured at 8 different doses
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess PK, Safety and Tolerability in Healthy SubjectsAcute Ischemic StrokeNCT06380699Changzhou Qianhong Bio-pharma Co., Ltd.56
已完成
1 期
Clinical Study of KD6001 in Advanced Solid TumoursSolid TumorNCT05230290Shanghai Kanda Biotechnology Co., Ltd.13
Unknown
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerChemotherapy-induced NeutropeniaNCT02725606Jiangsu T-Mab Biopharma Co.,Ltd30
已完成
1 期
A Trial of HRS-9813 in Healthy VolunteersHealthy VolunteersNCT06514963Guangdong Hengrui Pharmaceutical Co., Ltd50
已完成
1 期
A Trial of HRS-1893 in Healthy Volunteers and Patients With Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic CardiomyopathyNCT05879523Shandong Suncadia Medicine Co., Ltd.76